Top 3 drug approvals in oncology: March 2021

Written by Jade Parker, Senior Editor

Over the past month, several oncology drugs have been newly approved; in this piece we provide you with the key facts to keep you up-to-date with the industry news. Lorbrena (lorlatinib) Approved: 4 March 2021 Company: Pfizer (NY, USA) Indication: Adults with ALK-positive non-small-cell lung cancer Pfizer received positive news, earlier than expected, when the US label for Lorbrena (lorlatinib) was expanded under the US FDA’s Real-Time Oncology Review (RTOR) pilot programme. The decision, made 8 weeks ahead of the target date, means that lorlatinib is now approved for the first-line treatment of adults with ALK-positive non-small-cell lung cancer. Fotivda...

To view this content, please register now for access

It's completely free